Patient enrollment complete in Metadoxine Phase 3

|By:, SA News Editor

Alcobra (ADHD +1.1%) completes patient enrollment for its Phase 3 clinical trial evaluating the safety and efficacy of Metadoxine Extended Release (MDX) in adult ADHD patients.

The trial is a 300-patient, randomized placebo-controlled study at 18 sites in the U.S. and two sites in Israel. The primary endpoint is a statistically significant improvement in ADHD symptoms versus placebo as measured by the Conners' Adult ADHD Rating Scale.